Methods for characterizing, applying, and teaching CRISPR-Cas systems.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsBeisel, Chase L
MetadataShow full item record
AbstractNew drugs are desperately needed to combat methicillin-resistant Staphylococcus aureus (MRSA) infections. Here, we report screening commercial kinase inhibitors for antibacterial activity and found the anticancer drug sorafenib as major hit that effec-tively kills MRSA strains. Varying the key structural features led to the identification of a potent analogue, PK150, that showed antibacterial activity against several pathogenic strains at submicromolar concentrations. Furthermore, this antibiotic eliminated challenging persisters as well as established biofilms. PK150 holds promising therapeutic potential as it did not induce in vitro resistance, and shows oral bioavailability and in vivo efficacy. Analysis of the mode of action using chemical proteomics revealed several targets, which included interference with menaquinone biosynthesis by inhibiting demethylmenaquinone methyltrans-ferase and the stimulation of protein secretion by altering the activity of signal peptidase IB. Reduced endogenous menaquinone levels along with enhanced levels of extracellular proteins of PK150-treated bacteria support this target hypothesis. The associ-ated antibiotic effects, especially the lack of resistance development, probably stem from the compound’s polypharmacology.
CitationMethods. 2020 Jan 16. pii: S1046-2023(20)30020-7. doi: 10.1016/j.ymeth.2020.01.004.
AffiliationHIRI, Helmholtz-Institut für RNA-basierte Infektionsforschung, Josef-Shneider Strasse 2, 97080 Würzburg, Germany.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- CRISPR-Cas in the laboratory classroom.
- Authors: Trudel L, Frenette M, Moineau S
- Issue date: 2017 Feb 17
- A decade of discovery: CRISPR functions and applications.
- Authors: Barrangou R, Horvath P
- Issue date: 2017 Jun 5
- Diversity and evolution of class 2 CRISPR-Cas systems.
- Authors: Shmakov S, Smargon A, Scott D, Cox D, Pyzocha N, Yan W, Abudayyeh OO, Gootenberg JS, Makarova KS, Wolf YI, Severinov K, Zhang F, Koonin EV
- Issue date: 2017 Mar
- CRISPR-Cas experiments for schools and the public.
- Authors: Ziegler H, Nellen W
- Issue date: 2020 Feb 1
- History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology.
- Authors: Ishino Y, Krupovic M, Forterre P
- Issue date: 2018 Apr 1